Clinical trials: Depressive; Behavioral Disorder
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969150
- Testing
- Levomilnacipran ER
- Where
- 25 sites in United States
- Volunteers
- 362 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder, Major Depressive Episode
SAINT for MDD in an Inpatient Setting Follow-on
Randomized, multi-site, sham-controlled, double-blinded study
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
- Trial name
- NCT06462820
- Testing
- Active SAINT Stimulation
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Magnus Medical
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
- Trial name
- NCT05655507
- Testing
- Zuranolone
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Biogen
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Depression
Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder
This study is a phase II, randomized, double-blind, multi-center, placebo-controlled, parallel-group clinical trial and 150 subjects with depressive disorder will be enrolled.
- Trial name
- NCT07018245
- Testing
- TJ0113
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
Depressive Disorder, Major
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD- 2 (NCT07775300)
- Testing
- Brenipatide
- Where
- 170 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Bi-Polar Disorder
DELPhI Evaluation of Psychiatric Conditions
DELPhI acquisition and analysis software, a QuantalX Neuroscience development, which is designed to measure, analyze, and display brain electrical activity of human electroencephalogram (EEG), to transcranial magnetic stimulation…
- Conditions
- Major Depressive Disorder, Bi-Polar Disorder, ADHD, Schizophrenia
- Trial name
- NCT03842345
- Sponsor
- QuantalX Neuroscience
Major Depressive Disorder
Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents
This study is to verify the efficacy of fluvoxamine maleate given for 8 weeks in the treatment of children and adolescents with depression or depressive state
- Trial name
- NCT00353028
- Testing
- Fluvoxamine maleate
- Where
- 25 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Solvay Pharmaceuticals
Depressive Disorder, Major, Depression
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder…
- Conditions
- Depressive Disorder, Major, Depression, Depressive Disorder
- Trial name
- NCT02466477
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- 14 sites in Canada
- Volunteers
- 542 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder, Depression
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression.
- Conditions
- Major Depressive Disorder, Depression, Healthy
- Trial name
- NCT06570369
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder…
- Trial name
- AVENUE (NCT07227454)
- Testing
- Esketamine, Midazolam
- Where
- 44 sites in United States, Brazil and 5 more
- Volunteers
- 258 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder
Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder
The purpose of this study is to validate the effectiveness of using an integrated mobile sensing platform to deliver large-scale data-driven interventions to patients with depression.
- Trial name
- NCT02499094
- Testing
- Behavioral-data driven support
- Volunteers
- 1,004 people
- Sponsor
- Ginger.io
Major Depressive Disorder, Psychotic Disorders
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128505
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 104 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder
To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.
- Trial name
- NCT00242229
- Testing
- DVS-233 SR
- Volunteers
- 52 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode…
- Trial name
- AtWoRC (NCT02332954)
- Testing
- vortioxetine
- Where
- 26 sites in Canada
- Volunteers
- 226 people
- Sponsor
- Lundbeck Canada Inc.
Major Depressive Disorder (MDD)
Effects Of Antidepressants On Sexual Functioning In Adults
This study will evaluate the effects of two antidepression medications on sexual functioning.
- Trial name
- NCT00051272
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 425 people
- Sponsor
- GlaxoSmithKline
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data